Channing J Paller

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Management of bone metastases in refractory prostate cancer--role of denosumab
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Clin Interv Aging 7:363-72. 2012
  2. ncbi Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Hum Vaccin Immunother 8:509-19. 2012
  3. ncbi Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231, USA
    Drug Des Devel Ther 5:117-24. 2011

Detail Information

Publications3

  1. ncbi Management of bone metastases in refractory prostate cancer--role of denosumab
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Clin Interv Aging 7:363-72. 2012
    ..The role of denosumab in prostate cancer will continue to evolve either as monotherapy or in combination with other bone-targeting strategies...
  2. ncbi Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Hum Vaccin Immunother 8:509-19. 2012
    ....
  3. ncbi Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231, USA
    Drug Des Devel Ther 5:117-24. 2011
    ....